5505-16-8 Usage
Description
3,5-Diamino-2,4,6-triiodobenzoic acid is an organic compound derived from the metabolism of Diatrizoate, which is known for its mutagenic and cytotoxic properties. It is characterized by its brown solid appearance and is a significant metabolite in the context of its parent compound's biological and chemical behavior.
Uses
Used in Pharmaceutical Industry:
3,5-Diamino-2,4,6-triiodobenzoic acid is used as a chemical intermediate for the development of pharmaceutical products, particularly those aimed at addressing conditions related to its mutagenic and cytotoxic properties. Its role in the pharmaceutical industry is crucial for the synthesis of drugs that can potentially target specific biological pathways affected by its parent compound, Diatrizoate.
Used in Research and Development:
In the field of research and development, 3,5-diamino-2,4,6-triiodobenzoic acid serves as a valuable compound for studying the effects of Diatrizoate and its metabolites on cellular processes. Its mutagenic and cytotoxic properties make it an important subject for understanding the mechanisms of action and potential risks associated with exposure to Diatrizoate, which can inform the development of safer alternatives or mitigation strategies.
Used in Toxicology Studies:
3,5-Diamino-2,4,6-triiodobenzoic acid is utilized in toxicology studies to evaluate the potential hazards and risks associated with exposure to Diatrizoate. By examining the effects of this metabolite on cellular structures and functions, researchers can gain insights into the toxicological profile of Diatrizoate and develop appropriate safety measures and guidelines for its use in medical applications.
Used in Environmental Monitoring:
As a metabolite of Diatrizoate, 3,5-diamino-2,4,6-triiodobenzoic acid can be found in various environmental matrices, such as water and soil. It is used in environmental monitoring programs to assess the presence and concentration of Diatrizoate and its metabolites in the environment, which can help in understanding the potential ecological impacts and inform strategies for environmental protection and remediation.
Check Digit Verification of cas no
The CAS Registry Mumber 5505-16-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,5,0 and 5 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 5505-16:
(6*5)+(5*5)+(4*0)+(3*5)+(2*1)+(1*6)=78
78 % 10 = 8
So 5505-16-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H5I3N2O2.Na/c8-2-1(7(13)14)3(9)6(12)4(10)5(2)11;/h11-12H2,(H,13,14);/q;+1/p-1
5505-16-8Relevant articles and documents
A comparative study between three stability indicating spectrophotometric methods for the determination of diatrizoate sodium in presence of its cytotoxic degradation product based on two-wavelength selection
Riad, Safaa M.,El-Rahman, Mohamed K. Abd,Fawaz, Esraa M.,Shehata, Mostafa A.
, p. 254 - 259 (2015)
Abstract Three sensitive, selective, and precise stability indicating spectrophotometric methods for the determination of the X-ray contrast agent, diatrizoate sodium (DTA) in the presence of its acidic degradation product (highly cytotoxic 3,5-diamino metabolite) and in pharmaceutical formulation, were developed and validated. The first method is ratio difference, the second one is the bivariate method, and the third one is the dual wavelength method. The calibration curves for the three proposed methods are linear over a concentration range of 2-24 μg/mL. The selectivity of the proposed methods was tested using laboratory prepared mixtures. The proposed methods have been successfully applied to the analysis of DTA in pharmaceutical dosage forms without interference from other dosage form additives. The results were statistically compared with the official US pharmacopeial method. No significant difference for either accuracy or precision was observed.
Synthesis and evaluation of potential CT (computer tomography) contrast agents for bone structure and microdamage analysis
Parkesh, Raman,Gowin, Wolfgang,Lee, T. Clive,Gunnlaugsson, Thorfinnur
, p. 3611 - 3617 (2008/09/19)
The design and synthesis of several novel X-ray contrast agents 1-3, developed for targeting bone structures, and in particularly microcracks in bones, using CT (Computer Tomography) detection is described. These contrast agents are based on the use of the well known triiodobenzene platform, which was conjugated into one or more phenyliminodiacetate moieties, which can be used to 'lock' onto bone matrices. Compounds 1-3 were all tested for their ability to visualise cracks in bone structures (bovine bones) using μ-CT imaging. The Royal Society of Chemistry 2006.
